Antibacterial activity of LCB01-0062, a novel oxazolidinone

Sung Ji Jung; I. Na Rae Yun; Hee Soo Park; Hyun Hee Lee; Ji Woong Jeong; Yong Zu Kim; Young Lak Cho; Jin Hwan Kwak

doi:10.1016/j.ijantimicag.2012.07.017

Antibacterial activity of LCB01-0062, a novel oxazolidinone

Sung Ji Jung, I. Na Rae Yun, Hee Soo Park, Hyun Hee Lee, Ji Woong Jeong, Yong Zu Kim, Young Lak Cho, Jin Hwan Kwak

School of Food Science & Biotechnology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

LCB01-0062, a novel oxazolidinone, has potent antibacterial activity against clinical isolates of Gram-positive bacteria. The in vitro activity of LCB01-0062 was compared with that of linezolid, oxacillin, erythromycin, ciprofloxacin, vancomycin and quinupristin/dalfopristin. Among the tested agents, LCB01-0062 showed the most potent antibacterial activity against meticillin-resistant Staphylococcus aureus, meticillin-resistant coagulase-negative staphylococci and vancomycin-resistant enterococci. LCB01-0062 was 4-8-fold more active than linezolid, the first oxazolidinone drug, against Gram-positive bacteria. The time-kill curves of LCB01-0062 were analysed at concentrations of 0.5×, 1×, 2×, 4× and 8× the minimum inhibitory concentration against S. aureus strains. LCB01-0062 showed bacteriostatic activity during 24 h. LCB01-0062 was also more effective than linezolid against S. aureus in a systemic mouse model of infection.

Original language	English
Pages (from-to)	539-543
Number of pages	5
Journal	International Journal of Antimicrobial Agents
Volume	40
Issue number	6
DOIs	https://doi.org/10.1016/j.ijantimicag.2012.07.017
State	Published - Dec 2012

Keywords

LCB01-0062
MIC
Oxazolidinone
Systemic infection
Time-kill

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijantimicag.2012.07.017

Cite this

@article{b11a0046259845b8afb3fefdb0f60b36,

title = "Antibacterial activity of LCB01-0062, a novel oxazolidinone",

abstract = "LCB01-0062, a novel oxazolidinone, has potent antibacterial activity against clinical isolates of Gram-positive bacteria. The in vitro activity of LCB01-0062 was compared with that of linezolid, oxacillin, erythromycin, ciprofloxacin, vancomycin and quinupristin/dalfopristin. Among the tested agents, LCB01-0062 showed the most potent antibacterial activity against meticillin-resistant Staphylococcus aureus, meticillin-resistant coagulase-negative staphylococci and vancomycin-resistant enterococci. LCB01-0062 was 4-8-fold more active than linezolid, the first oxazolidinone drug, against Gram-positive bacteria. The time-kill curves of LCB01-0062 were analysed at concentrations of 0.5×, 1×, 2×, 4× and 8× the minimum inhibitory concentration against S. aureus strains. LCB01-0062 showed bacteriostatic activity during 24 h. LCB01-0062 was also more effective than linezolid against S. aureus in a systemic mouse model of infection.",

keywords = "LCB01-0062, MIC, Oxazolidinone, Systemic infection, Time-kill",

author = "Jung, \{Sung Ji\} and Yun, \{I. Na Rae\} and Park, \{Hee Soo\} and Lee, \{Hyun Hee\} and Jeong, \{Ji Woong\} and Kim, \{Yong Zu\} and Cho, \{Young Lak\} and Kwak, \{Jin Hwan\}",

year = "2012",

month = dec,

doi = "10.1016/j.ijantimicag.2012.07.017",

language = "English",

volume = "40",

pages = "539--543",

journal = "International Journal of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - Antibacterial activity of LCB01-0062, a novel oxazolidinone

AU - Jung, Sung Ji

AU - Yun, I. Na Rae

AU - Park, Hee Soo

AU - Lee, Hyun Hee

AU - Jeong, Ji Woong

AU - Kim, Yong Zu

AU - Cho, Young Lak

AU - Kwak, Jin Hwan

PY - 2012/12

Y1 - 2012/12

N2 - LCB01-0062, a novel oxazolidinone, has potent antibacterial activity against clinical isolates of Gram-positive bacteria. The in vitro activity of LCB01-0062 was compared with that of linezolid, oxacillin, erythromycin, ciprofloxacin, vancomycin and quinupristin/dalfopristin. Among the tested agents, LCB01-0062 showed the most potent antibacterial activity against meticillin-resistant Staphylococcus aureus, meticillin-resistant coagulase-negative staphylococci and vancomycin-resistant enterococci. LCB01-0062 was 4-8-fold more active than linezolid, the first oxazolidinone drug, against Gram-positive bacteria. The time-kill curves of LCB01-0062 were analysed at concentrations of 0.5×, 1×, 2×, 4× and 8× the minimum inhibitory concentration against S. aureus strains. LCB01-0062 showed bacteriostatic activity during 24 h. LCB01-0062 was also more effective than linezolid against S. aureus in a systemic mouse model of infection.

AB - LCB01-0062, a novel oxazolidinone, has potent antibacterial activity against clinical isolates of Gram-positive bacteria. The in vitro activity of LCB01-0062 was compared with that of linezolid, oxacillin, erythromycin, ciprofloxacin, vancomycin and quinupristin/dalfopristin. Among the tested agents, LCB01-0062 showed the most potent antibacterial activity against meticillin-resistant Staphylococcus aureus, meticillin-resistant coagulase-negative staphylococci and vancomycin-resistant enterococci. LCB01-0062 was 4-8-fold more active than linezolid, the first oxazolidinone drug, against Gram-positive bacteria. The time-kill curves of LCB01-0062 were analysed at concentrations of 0.5×, 1×, 2×, 4× and 8× the minimum inhibitory concentration against S. aureus strains. LCB01-0062 showed bacteriostatic activity during 24 h. LCB01-0062 was also more effective than linezolid against S. aureus in a systemic mouse model of infection.

KW - LCB01-0062

KW - MIC

KW - Oxazolidinone

KW - Systemic infection

KW - Time-kill

UR - https://www.scopus.com/pages/publications/84869500947

U2 - 10.1016/j.ijantimicag.2012.07.017

DO - 10.1016/j.ijantimicag.2012.07.017

M3 - Article

C2 - 23058227

AN - SCOPUS:84869500947

SN - 0924-8579

VL - 40

SP - 539

EP - 543

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - 6

ER -

Antibacterial activity of LCB01-0062, a novel oxazolidinone

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this